Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Annexon Biosciences (ANNX)
NASDAQ:ANNX
Annexon Biosciences (ANNX) Stock Price & Analysis
787 Followers
ANNX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.57 - $8.40
Previous Close$5.63
Volume227.57K
Average Volume (3M)3.01M
Market Cap
$595.59M
Enterprise Value$359.32M
Total Cash (Recent Filing)$264.95M
Total Debt (Recent Filing)$30.79M
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Aug 05, 2024EPS Estimate
-$0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.46
Shares Outstanding92,412,866
10 Day Avg. Volume2,246,922
30 Day Avg. Volume3,008,136
Standard Deviation0.27
R-Squared0.06
Alpha-0.00941
Financial Highlights & Ratios
Price to Book (P/B)1.84
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue128.33
Enterprise Value/Gross Profit179.66
Enterprise Value/Ebitda-3.90
Forecast
1Y Price Target
$17.50Price Target Upside209.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Annexon Biosciences News
Bulls Say, Bears Say
Bulls Say
Efficacy'005 treatment was also associated with reduction in days on ventilation and faster time to walk independently.
Market Potential'005 could be the first approved therapy for GBS in the US.
Safety'005 had a favorable safety profile and was well tolerated.
Bears Say
Market AdoptionA paradigm shift towards ‘005 could take time, with some potentially even considering using the two in combination at first.
Research And DevelopmentLonger-term follow up data is needed for ‘005.
Stock VolatilityShares have been very volatile as of late.
---
Ownership Overview
18.68% Insiders
17.86% Mutual Funds
8.55% Other Institutional Investors
54.90% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ANNX FAQ
What was Annexon Biosciences’s price range in the past 12 months?
Annexon Biosciences lowest stock price was $1.57 and its highest was $8.40 in the past 12 months.
What is Annexon Biosciences’s market cap?
Currently, no data Available
When is Annexon Biosciences’s upcoming earnings report date?
Annexon Biosciences’s upcoming earnings report date is Aug 05, 2024 which is in 14 days.
How were Annexon Biosciences’s earnings last quarter?
Annexon Biosciences released its earnings results on May 13, 2024. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.34 by $0.13.
Is Annexon Biosciences overvalued?
According to Wall Street analysts Annexon Biosciences’s price is currently Undervalued.
Does Annexon Biosciences pay dividends?
Annexon Biosciences does not currently pay dividends.
What is Annexon Biosciences’s EPS estimate?
Annexon Biosciences’s EPS estimate is -$0.23.
How many shares outstanding does Annexon Biosciences have?
Annexon Biosciences has 105,413,990 shares outstanding.
What happened to Annexon Biosciences’s price movement after its last earnings report?
Annexon Biosciences reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.34. Following the earnings report the stock price went up 2.526%.
Which hedge fund is a major shareholder of Annexon Biosciences?
Among the largest hedge funds holding Annexon Biosciences’s share is GMT Capital Corp. It holds Annexon Biosciences’s shares valued at 19M.
---
Annexon Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.50 (209.73% Upside)
$17.50 (209.73% Upside)
Blogger Sentiment
Bullish
ANNX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 360.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
52.16%
12-Months-Change
Fundamentals
Return on Equity
-50.60%
Trailing 12-Months
Asset Growth
13.13%
Trailing 12-Months
Company Description
Annexon Biosciences
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005; ANX007; and ANX009.
---
ANNX Stock 12 Month Forecast
Average Price Target
$17.50
▲(209.73% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Crispr Therapeutics AG
―
Intra-Cellular Therapies
―
Sarepta Therapeutics
―
Best Analysts Covering ANNX
1 Year
1 Year Success Rate
5/12 ratings generated profit
1 Year Average Return
+17.05%
reiterated a buy rating 2 months ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 41.67% of your transactions generating a profit, with an average return of +17.05% per trade.
---